Document is current

Article History

Received: 26 September 2022

Revised: 7 February 2023

Accepted: 7 February 2023

First Online: 20 February 2023

Declarations

:

: KT has received honorarium from Sysmex. YI has received honorarium from Novartis, Janssen, Meiji Seika Pharma, and Kyowa Kirin. SM has received honorarium from Celgene/Bristol Myers Squibb, Chugai, CSL Behring, Daiichi-Sankyo, Eisai, Novartis, SymBio, and Takeda, and has a consulting or advisory role of Takeda, Celgene/BMS, Daiichi-Sankyo, Novartis, Celgene/Bristol Myers Squib, Gilead Sciences, and Genmab. SF has received honorarium from Janssen, Takeda, Zenyaku, Otsuka, Astrazeneca, Abbvie, Ono, and Chugai, and a research fund from Chugai and Loxo Oncology. KK has received a research fund from Otsuka Pharmaceutical and honorarium from Otsuka Pharmaceutical and Bristol Myers Squibb. KI has received honorarium from Eisai, Chugai, Janssen, AstraZeneca, Novartis, Bristol Myers Squibb, Celgene, Kyowa Kirin, Abbvie, Ono Pharmaceutical, Eli Lilly, MSD, Daiichi Sankyo, Kyorin Pharmaceutical, Symbio, Takeda, Allergan Japan, and FIJIFILM Toyama Chemical, and a research grant from Celgene/Bristol Myers Squibb, MSD, AstraZeneca, AbbVie, Eisai, Incyte, Solasia Pharma, Novartis, Bayer, Pfizer, Janssen, Yakult, Kyowa Kirin, Ono Pharmaceutical, Daiichi Sankyo, Chugai, Takeda, Beigene, Genmab, Otsuka, and LOXO Oncology, and has a consulting or advisory role of Kyowa Kirin, Eisai, Genmab, AbbVie, Ono Pharmaceutical, Daiichi Sankyo, Takeda, Celgene, and AstraZeneca. Other authors declare no conflict of interest.

: Informed consent was obtained from the patient for the publication of this case report.